EcoR1 Capital

Venture Capital

Biotechnology-focused investment fund specializing in public and private life sciences companies.

Profile

Headquarters
San Francisco, US
Investments
2
Companies
2

Capital

Total Deployed
$345M
Lead Rounds
0
Website
www.ecor1cap.com

Portfolio

2 companies
Freenome $1.3B
Private South San Francisco, California, United States

Biotech company developing AI-powered multiomics blood tests for early cancer detection. Its platform analyzes cell-free DNA, methylation patterns, and protein biomarkers from routine blood draws to screen for cancers in their earliest stages. Lead product SimpleScreen targets FDA approval for colorectal cancer screening.
Pardes Biosciences $127M
Acquired Carlsbad, US

Clinical-stage biopharmaceutical company that developed novel oral antiviral therapeutics targeting COVID-19. Went public via SPAC merger in 2021 before being acquired by MediPacific (a Foresite Capital affiliate) in 2023 after its lead candidate failed Phase 2 trials.

Investment data is compiled from multiple independent sources including company announcements, press coverage, and regulatory filings. While we strive for accuracy, amounts and dates may reflect reported figures at time of announcement.